What is DSIP?
DSIP stands for delta sleep-inducing peptide. The name reflects its research history, while actual sleep outcomes require direct measurement.
Biological role or research focus
Experimental sleep regulation.
The name “sleep-inducing” is not proof of a meaningful improvement in chronic insomnia.
Role reference: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗
Names you may encounter
emideltide · delta sleep inducing peptide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Experimental sleep-related peptide
- Main research area
- Sleep physiology
- Evidence featured
- Small blinded human study
- Source check
- October 4, 2026
Quick answers
- Is DSIP FDA approved?
- No. No FDA-approved drug contains DSIP. Source ↗
- Is DSIP safe?
- DSIP (emideltide) is unapproved. Small, older human studies exist, but FDA judged its safety insufficiently characterized and noted headache, nausea, vertigo and low blood pressure reports. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is DSIP banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
- Has the FDA taken action over DSIP?
- Yes. Our records list 2 FDA actions naming it, most recently on July 1, 2026: FDA presented emideltide (DSIP) to its Pharmacy Compounding Advisory Committee (July 24, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Chronic insomnia experiment (1992) | Small blinded human study | 16 people with chronic insomnia. |
| DSIP · six-volunteer sleep experiment (1981) | Small human crossover study | Six healthy volunteers, four men and two women. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Small blinded human study · 1992
Chronic insomnia experiment
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
- Population / model
- 16 people with chronic insomnia.
- Study design
- Matched-pairs parallel groups; five laboratory nights including baseline, followed by three treatment nights.
- Main finding
- Some objective sleep measures changed modestly, but subjective sleep quality did not improve. The authors considered major short-term therapeutic benefit unlikely.
- Limits & context
- The small sample, short duration, and partly placebo-driven differences limit confidence. The name “delta sleep-inducing peptide” is not itself evidence of an insomnia treatment.
Small human crossover study · 1981
DSIP · six-volunteer sleep experiment
How does an early sleep signal compare with the later insomnia trial?
- Population / model
- Six healthy volunteers, four men and two women.
- Study design
- Double-blind crossover experiment with placebo, short-term sleep monitoring, and subsequent-night measurements.
- Main finding
- Median total sleep time increased 59% within a 130-minute observation interval. Shorter sleep onset and improved sleep efficiency were reported for the following night.
- How to read it
- The percentage describes a short observation window, not a sustained increase in nightly sleep or successful treatment of chronic insomnia.
- Limits & context
- Six healthy participants and brief monitoring cannot establish long-term efficacy or uncommon harms. Read alongside the later 16-person insomnia study, which found limited benefit. Absence of observed side effects is not proof of safety.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming DSIP as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Search additional PubMed records ↗Risks & interactions
DSIP (emideltide) is unapproved. Small, older human studies exist, but FDA judged its safety insufficiently characterized and noted headache, nausea, vertigo and low blood pressure reports.
Small intravenous studies in insomnia reported no significant adverse effects; studies in drug or alcohol withdrawal reported side effects that withdrawal itself may confound. FDA found no safety data for the subcutaneous route proposed for compounding.
Unassessed: little human safety data
Take extra care with: Heart or blood pressure problems
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- Progressive low blood pressure reported after a repeat infusion in withdrawal studies (FDA review)
- FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products
Side effects reported in studies
- headache
- nausea
- vertigo
- sweating
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA briefing document: emideltide (DSIP) (Pharmacy Compounding Advisory Committee, 2026) ↗ · FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · DSIP in chronic insomnia: double-blind study (1992) ↗ · DSIP effects on human sleep behavior (1981) ↗
Safety evidence & remaining uncertainty
FDA identifies a safety-data gap. The small sleep study cannot characterize uncommon adverse effects or repeated long-term exposure.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Emideltide (DSIP)". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA presented emideltide (free base and acetate) to its Pharmacy Compounding Advisory Committee on July 24, 2026, proposing that it NOT be added to the 503A bulks list. source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
FDA actions
- FDA presented emideltide (DSIP) to its Pharmacy Compounding Advisory Committee (July 24, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. The committee's vote is advisory; no final FDA decision found. (2026-07) source
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing DSIP among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
The selected insomnia experiment provides limited human evidence, with weak objective changes and no subjective sleep-quality benefit. It does not establish a routine treatment for chronic insomnia.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
DSIP has been examined as a modulator of sleep. Its name does not specify a clinically established mechanism or guarantee an effect on restorative sleep.
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- The name “sleep-inducing” is not proof of a meaningful improvement in chronic insomnia.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does “sleep-inducing” mean proven insomnia treatment?
No. A compound name can outlast the hypothesis that produced it. The controlled findings matter more.
Were participants simply asked whether they slept better?
The study used objective sleep recordings as well as subjective measures, and the two did not show a consistent benefit.
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Small double-blind human study · PMID 1299794 ↗
- DSIP · six-volunteer sleep experiment · 1981 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
